Methods and Animal Model for Analyzing Age-Related Macular Degeneration by Ambati, Jayakrishna
University of Kentucky
UKnowledge
Ophthalmology and Visual Science Faculty Patents Ophthalmology and Visual Science
9-29-2009
Methods and Animal Model for Analyzing Age-
Related Macular Degeneration
Jayakrishna Ambati
University of Kentucky, jayakrishna.ambati@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/ophthalmology_patents
Part of the Ophthalmology Commons
This Patent is brought to you for free and open access by the Ophthalmology and Visual Science at UKnowledge. It has been accepted for inclusion in
Ophthalmology and Visual Science Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Recommended Citation
Ambati, Jayakrishna, "Methods and Animal Model for Analyzing Age-Related Macular Degeneration" (2009). Ophthalmology and
Visual Science Faculty Patents. 19.
https://uknowledge.uky.edu/ophthalmology_patents/19
(12) United States Patent 
J ayakrishna 
US007595430B2 
US 7,595,430 B2 
Sep. 29, 2009 
(10) Patent N0.: 
(45) Date of Patent: 
(54) METHODS AND ANIMAL MODEL FOR 
ANALYZING AGE-RELATED MACULAR 
DEGENERATION 
(75) Inventor: Ambati J ayakrishna, Lexington, KY 
(Us) 
(73) Assignee: University of Kentucky Research 
Foundation, Lexington, KY (U S) 
( * ) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 785 days. 
(21) App1.No.: 10/685,705 
(22) Filed: Oct. 16, 2003 
(65) Prior Publication Data 
US 2004/0177387 A1 Sep. 9, 2004 
Related US. Application Data 
(60) Provisional application No. 60/422,096, ?led on Oct. 
30, 2002. 
(51) Int. Cl. 
G01N 33/00 (2006.01) 
A01K 67/027 (2006.01) 
(52) US. Cl. ........................................... .. 800/3; 800/18 
(58) Field of Classi?cation Search ................... .. 800/3, 
800/ 18 
See application ?le for complete search history. 
(56) References Cited 
OTHER PUBLICATIONS 
Doetschman, T. (1999) Interpretation of phenotype in genetically 
engineered mice. Laboratory Animal Science 49(2): 137-143.* 
Donehower et al. (1995) Effects of genetic background on 
tumorigenesis in p53-de?cient mice. Molecular Carcinogenesis 14: 
16-22.* 
Jacks et al. (1992) Effects of an Rb mutation in the mouse. Nature 
359: 295-300.* 
Jaenisch et al. (1988) Transgenic Animals. Science 240: 1468-1474.* 
Kuehn et al. (1987) A potential animal model for Lesch-Nyhan syn 
drome through introduction of HPRT mutations into mice. Nature 
326: 295-298.* 
Moens et al. (1993) Defects in heart and lung development in com 
pound heterozygotes for two different targeted mutations at the 
N-myc locus. Development 119: 485-499* 
Petridou et al. (2003) Heterogeneous inducible mammary-speci?c 
expression of JAB/SOCSl in lactating transgenic mice is associated 
With no obvious phenotype, even at the cellular level. Transgenic 
Research 12: 693-706.* 
Sigmund, CD (2000) Viewpoint: Are studies in genetically altered 
mice out of control? Arterioscler. Thromb. Vasc. Biol. 20: 1425 
1429* 
Lu, Bao., et al, “Abnormalities in Monocyte Recruitment and 
Cytokine Expression in Monocyte Chemoattractant Protein l-de? 
cient Mice” J. Exp. Med, Feb. 16, 1998, vol. 187(4), pp. 601-608, 
ISSN 0022-1007. 
KuZiel, William, A.., et al. “Severe reduction in leukocyte adhesion 
and monocyte extravasation in mice de?cient in CC Chemokine 
receptor 2” Proceeding of the National Academy of the Sciences, 
USA, vol. 94, No. 22, Oct. 1997, pp. 12053-12058. 
Raisler, Brian J., et al. “Adeno-associated virus type-2 expression of 
pigmented epithelium-derived factor or Kringles 1-3 of angiostatin 
reduce retinal neovascularization” PNAS, Jun. 25, 2002, vol. 99, No. 
13, pp. 8909-8914. 
Acland, Gregory, M., et al. “Gene therapy restores vision in canine 
model of childhood blindness.” Nature Genetics, vol. 28, May 2001, 
pp. 92-95. 
Elner, Victor, M., et al. “Cell-Associated Human Retinal Pigment 
Epithelium Interleukin-8 and Monocyte Chemotactic Protein-1: 
Immunochemical and In-situ Hybridization Analyses.” Experimental 
Eye Research, Dec. 1997, vol. 65, No. 6, pp. 781-789. 
Ambati, J. et al. “An animal model of age-related macular degenera 
tion in senescent macrophage recruitment impaired mice” Associa 
tion for Research in Vision Opthalmology Annual Meeting Abstract 
Search and Program Planner, 2003. 
Grossniklaus, H. et al. “Macrophage and retinal pigment epithelium 
expression of angiogenic cytokines in choroidal neovascularization” 
Molecular Vision, 2002, vol. 8, pp. 119-126. 
* cited by examiner 
Primary ExamineriAnne-Marie Falk 
(74) Attorney, Agent, or FirmiMcDermott Will & Emery 
LLP 
(57) ABSTRACT 
Methods for testing candidate drugs for treatment of age 
related macular degeneration are provided. Ccl2-de?cient, 
and Ccr2-de?cient mice are used to determine the effect of 
candidate drugs and treatments on development of age-re 
lated macular degeneration. Also provided is a Ccl2-de? 
cient, Ccr2-de?cient dual knockout mouse, Which is a useful 
animal model for age-related macular degeneration. 
27 Claims, 23 Drawing Sheets 
(6 of 23 Drawing Sheet(s) Filed in Color) 
US 7,595,430 B2 Sep. 29, 2009 Sheet 1 0f 23 US. Patent 
US 7,595,430 B2 Sep. 29, 2009 Sheet 2 0f 23 US. Patent 
US. Patent Sep. 29, 2009 Sheet 3 0f 23 US 7,595,430 B2 




US. Patent Sep. 29, 2009 Sheet 5 0f 23 US 7,595,430 B2 
Sep. 29, 2009 Sheet 6 0f 23 US 7,595,430 B2 US. Patent 
US. Patent 
Figure 7A 




































































































































































































































































































US. Patent Sep. 29, 2009 Sheet 8 0f 23 US 7,595,430 B2 
901 aggctcctca agaggcacaa gcaaagcagg gctcgagttg atttgttctc tcttcatcct 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10021 tgcactccag cctgggcaac agagccagac tccatctcaa aaaaaaaaaa aaa 
Figure 8D 
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FIGURE 9 
SEQ ID NO. 9: Human C5 receptor gene: 
1 ctacetccaa ccatgggcct tttgggaata ctttgttttt taatcttcct ggggaaaacc 
61 tggggacagg agcaaacata tgtcatttca gcaccaaaaa tattccgtgt tggagcatct 
121 gaaaatattg tgattcaagt ttatggatac actgaagcat ttgatgcaac aatctctatt 
181 aaaagttatc ctgataaaaa atttagttac tcctcaggcc atgttcattt atcctcagag 
241 aataaattcc aaaactctgc aatcttaaca atacaaccaa aacaattgcc tggaggacaa 
301 aacccagttt cttatgtgta tttggaagtt gtatcaaagc atttttcaaa atcaaaaaga 
361 atgccaataa cctatgacaa tggatttctc ttcattcata cagacaaacc tgtttatact 
421 ccagaccagt cagtaaaagt tagagtttat tcgttgaatg acgacttgaa gccagccaaa 
481 agagaaactg tcttaacctt catagatcct gaaggatcag aagttgacat ggtagaagaa 
541 attgatcata ttggaattat ctcttttcct gacttcaaga ttccgtctaa tcctagatat 
601 ggtatgtgga cgatcaaggc taaatataaa gaggactttt caacaactgg aaccgcatat 
661 tttgaagtta aagaatatgt cttgccacat ttttctgtct caatcgagcc agaatataat 
721 ttcattggtt acaagaactt taagaatttt gaaattacta taaaagcaag atatttttat 
781 aataaagtag tcactgaggc tgacgtttat atcacatttg gaataagaga agacttaaaa 
841 gatgatcaaa aagaaatgat gcaaacagca atgcaaaaca caatgttgat aaatggaatt 
901 gctcaagtca catttgattc tgaaacagca gtcaaagaac tgtcatacta cagtttagaa 
961 gatttaaaca acaagtacct ttatattgct gtaacagtca tagagtctac aggtggattt 
1021 tctgaagagg cagaaatacc tggcatcaaa tatgtcctct ctccctacaa actgaatttg 
1081 gttgctactc ctcttttcct gaagcctggg attccatatc ccatcaaggt gcaggttaaa 
1141 gattcgcttg accagttggt aggaggagtc ccagtaatac tgaatgcaca aacaattgat 
1201 gtaaaccaag agacatetga cttggatcca agcaaaagtg taacacgtgt tgatgatgga 
1261 gtagcttcct ttgtgcttaa tctcccatct ggagtgacgg tgctggagtt taatgtcaaa 
1321 actgatgctc cagatcttcc agaagaaaat caggccaggg aaggttaccg agcaatagca 
1381 tactcatctc tcagccaaag ttacctttat attgattgga ctgataacca taaggctttg 
1441 ctagtgggag aacatctgaa tattattgtt acccccaaaa gcccatatat tgacaaaata 
1501 actcactata attacttgat tttatccaag ggcaaaatta tccattttgg cacgagggag 
1561 aaattttcag atgcatctta tcaaagtata aacattccag taacacagaa catggttcct 
1621 tcatcccgac ttctggtcta ttatatcgtc acaggagaac agacagcaga attagtgtct 
1681 gattcagtct ggttaaatat tgaagaaaaa tgtggcaacc agctccaggt tcatctgtct 
1741 cctgatgcag atgcatattc tccaggccaa actgtgtctc ttaatatggc aactggaatg 
1801 gattcctggg tggcattagc agcagtggac agtgctgtgt atggagtcca aagaggagcc 
1861 aaaaagccct, tggaaagagt atttcaattc ttagagaaga gtgatctggg ctgtggggca 
1921 ggtggtggcc tcaacaatgc caatgtgttc cacctagctg gacttacctt cctcactaat 
1981 gcaaatgcag atgactccca agaaaatgat gaaccttgta aagaaattct caggccaaga 
2041 agaacgctgc aaaagaagat agaagaaata gctgctaaat ataaacattc agtagtgaag 
2101 aaatgttgtt acgatggagc ctgcgttaat aatgatgaaa cctgtgagca gcgagctgca 
2161 cggattagtt tagggccaag atgcatcaaa gctttcactg aatgttgtgt cgtcgcaagc 
2221 cagctccgtg ctaatatctc tcataaagac atgcaattgg gaaggctaca catgaagacc 
2281 ctgttaccag taagcaagcc agaaattcgg agttattttc cagaaagctg gttgtgggaa 
2341 gttcatcttg ttcccagaag aaaacagttg cagtttgccc tacctgattc tctaaccacc 
2401 tgggaaattc aaggcattgg catttcaaac actggtatat gtgttgctga tactgtcaag 
2461 gcaaaggtgt tcaaagatgt cttcctggaa atgaatatac catattctgt tgtacgagga 
2521 gaacagatcc aattgaaagg aactgtttac aactatagga cttctgggat gcagttctgt 































